These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36351646)

  • 1. [Acute myeloid leukemia harboring NUP98::DDX10].
    Kurita N; Kato T; Nanmoku T; Maruyama Y; Suehara Y; Hattori K; Sakamoto T; Yokoyama Y; Yoshida C; Tsuboi Y; Obara N; Nishikii H; Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2022; 63(10):1397-1401. PubMed ID: 36351646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of monitoring NUP98::NSD1 fusion genes before and after allogeneic hematopoietic stem cell transplantation].
    Shang YK; Pan XA; Chang YJ; Qin YQ; Wang Y; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1010-1015. PubMed ID: 38503524
    [No Abstract]   [Full Text] [Related]  

  • 3. Inversion (11)(p15q22) with NUP98-DDX10 fusion gene in pediatric acute myeloid leukemia.
    Morerio C; Acquila M; Rapella A; Tassano E; Rosanda C; Panarello C
    Cancer Genet Cytogenet; 2006 Dec; 171(2):122-5. PubMed ID: 17116492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review.
    Fu W; Huang A; Cheng H; Luo Y; Gao L; Tang G; Yang J; Wang J; Ni X
    BMC Med Genomics; 2021 May; 14(1):130. PubMed ID: 34001105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif.
    Yassin ER; Abdul-Nabi AM; Takeda A; Yaseen NR
    Leukemia; 2010 May; 24(5):1001-11. PubMed ID: 20339440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
    Gaut D; Oliai C; Boiarsky J; Zhang S; Salhotra A; Azenkot T; Kennedy VE; Khanna V; Olmedo Gutierrez K; Shukla N; Moskoff B; Park G; Afkhami M; Patel A; Jeyakumar D; Mannis G; Logan AC; Jonas BA; Schiller G
    Leuk Lymphoma; 2024 Jan; 65(1):69-77. PubMed ID: 37801340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inv(11)(p15q22)/NUP98-DDX10 fusion and isoforms in a new case of de novo acute myeloid leukemia.
    Gorello P; Nofrini V; Brandimarte L; Pierini V; Crescenzi B; Nozza F; Daniele G; Storlazzi CT; Di Giacomo D; Matteucci C; La Starza R; Mecucci C
    Cancer Genet; 2013 Mar; 206(3):92-6. PubMed ID: 23522748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inv(11)(p15q22) chromosome translocation of therapy-related myelodysplasia with NUP98-DDX10 and DDX10-NUP98 fusion transcripts.
    Ikeda T; Ikeda K; Sasaki K; Kawakami K; Takahara J
    Int J Hematol; 1999 Apr; 69(3):160-4. PubMed ID: 10222653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare NUP98::PRRX1 fusion transcript in a therapy-related acute myeloid leukemia associated with del(7q) following chemotherapy for diffuse large B-cell lymphoma.
    Wang Y; Zhang Z; Wang L; Wang H; Dong F
    Cancer Genet; 2024 Jun; 284-285():12-15. PubMed ID: 38493578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangement.
    Gallego Hernanz MP; Torregrosa Diaz JM; Sorel N; Bobin A; Dindinaud E; Bouyer S; Desmier D; Brizard F; Leleu X; Maillard N; Chomel JC
    Cancer Med; 2019 Apr; 8(4):1765-1770. PubMed ID: 30848074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
    Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang Y; Zhou Z; Yan H; You Y
    Front Immunol; 2022; 13():810284. PubMed ID: 35185899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor - Hematopoietic Stem Cell Transplantation: Single Center Experience.
    Panovska-Stavridis I; Pivkova-Veljanovska A; Ridova N; Stojanovski Z; Cadievski L; Trajkova S; Popova-Labacevska M; Matevska-Geshkovska N; Cevreska L; Georgievski B; Dimovski A
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Dec; 41(3):5-12. PubMed ID: 33500364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.